Toggle Main Menu Toggle Search

Open Access padlockePrints

Haemophilus influenzae type b immunization in infants in the United Kingdom: Effects of diphtheria/tetanus/acellular pertussis/Hib combination vaccine, significant prematurity, and a fourth dose

Lookup NU author(s): Dr Janet Berrington, Professor Andrew Cant, Professor John Matthews, Dr Marilyn O'Keeffe, Dr Gavin Spickett, Dr Alan Fenton

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

OBJECTIVE. To measure anti-polyribosylribitolphosphate (PRP) antibody and anti-tetanus toxoid (TT) antibody responses in UK infants to explore the effects of (1) immunization with an acellular diphtheria/tetanus/pertussis/Haemophilus influenzae type b (DTPHib) combination vaccine, (2) significant preterm delivery, and (3) a fourth dose of conjugated Hib vaccine (PRP-T) in those with a low anti-PRP antibody (<1.0 μg/mL) after primary immunization. METHODS. A prospective study was conducted in 4 tertiary neonatal units at a time when 2 types of DTPHib vaccines were used interchangeably in the United Kingdom for primary immunization: acellular (DTPaHib) and whole cell. Timing and type of all vaccine doses were as per standard UK practice. Blood was taken before and after immunization. A total of 166 preterm and 45 term infants completed the study; 97 (15 term) infants who had anti-PRP antibody <1.0 μg/mL were offered a fourth dose of PRP-T; 61 (55 preterm) then had repeat antibody measurements. Anti-PRP and anti-TT antibody after primary immunization relative to gestation and number of whole cell vaccine doses received was measured, as well as anti-PRP antibody after a fourth dose of PRP-T. RESULTS. A total of 49% of preterm and 33% of term infants had anti-PRP antibody <1.0 μg/mL after full primary immunization. Receipt of 1 or more acellular vaccine doses was associated with lower anti-PRP antibody, a dose response effect being observed. Preterm infants were less likely to have anti-PRP antibody >1.0 μg/mL compared with term infants. A total of 93% of infants who were given a fourth dose had anti-PRP antibody >1.0 μg/mL. Anti-TT antibody responses were satisfactory for all infants but also reduced by each DTPaHib dose received. CONCLUSION. Infants who receive DTPaHib, are significantly preterm, or who do not receive a fourth dose of conjugated Hib vaccine may be at increased risk for Hib disease. Copyright © 2006 by the American Academy of Pediatrics.


Publication metadata

Author(s): Berrington JE, Cant AJ, Matthews JNS, O'Keeffe M, Spickett GP, Fenton AC

Publication type: Article

Publication status: Published

Journal: Pediatrics

Year: 2006

Volume: 117

Issue: 4

Pages: e717-e724

ISSN (print): 0031-4005

ISSN (electronic): 1098-4275

Publisher: American Academy of Pediatrics

URL: http://dx.doi.org/10.1542/peds.2005-0348

DOI: 10.1542/peds.2005-0348

PubMed id: 16549502


Altmetrics

Altmetrics provided by Altmetric


Actions

Find at Newcastle University icon    Link to this publication


Share